Drugs / TQC2938
Trials 3
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT06449859 | Jun 2023 → Nov 2024 | asthma | Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd. | Unknown | No outcome recorded |
| Phase 22 trials | ||||||
| Phase 2 | NCT07052097 | Jul → Sep 2025 | seasonal allergic rhinitis | Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd. | Completed | No outcome recorded |
| Phase 2 | NCT06789289 | Mar 2025 → Mar 2027 expected | chronic obstructive pulmonary disease | Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd. | Active not recruiting | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | TQC2938 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06789289 ↗ |
| Modality | Monoclonal antibody | “TQC2938 injection is a humanized monoclonal antibody” NCT06449859 ↗ |
| Route | Subcutaneous | “administered as a single dose of subcutaneous (SC) injection.” NCT06449859 ↗ |